
Join to View Full Profile
102 Endicott StDanvers, MA 01923
Phone+1 978-882-6060
Dr. Harris is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Katherine Harris is an oncologist located in Boston, MA, specializing in breast cancer. She completed her fellowship in Hematology and Medical Oncology and her residency in Internal Medicine at the University of California, San Francisco, following her graduation from Pennsylvania State University College of Medicine. Her published research includes studies on breast cancer diagnostics and treatment, with several works cited multiple times in other publications. She has been recognized with awards such as the Patient-Centered Specialty Practice Recognition from the National Committee for Quality Assurance and Meaningful Use Stage 1 Certification from the Centers for Medicare & Medicaid Services.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1997 - 2000
University of California (San Francisco)Residency, Internal Medicine, 1994 - 1997
Pennsylvania State University College of MedicineClass of 1994
Certifications & Licensure
MA State Medical License 2016 - 2027
PA State Medical License 2002 - 2018
CA State Medical License 1996 - 2001
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2012, 2014-2016
- CMS Meaningful Use Stage 2 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2012, 2014-2016
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
Publications & Presentations
PubMed
- 39 citationsDiscovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.Andreas Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce
Cancer Discovery. 2024-02-08 - 7 citationsAxillary Ultrasound Evaluation in Breast Cancer Patients: A Multidisciplinary Viewpoint and Middle Ground.Mansi Saksena, Rachel Jimenez, Suzanne Coopey, Katherine Harris
Journal of Breast Imaging. 2021-11-16 - 4 citationsBaseline Screening MRI Uptake and Findings in Women with ≥ 20% Lifetime Risk of Breast Cancer.Alison Laws, Therese M. Mulvey, Nicole Jalbert, Sarah Dalton, Olga Kantor
Annals of Surgical Oncology. 2020-07-18
Press Mentions
Mgh Cancer Center DanversMarch 16th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









